Targeting transcription factors for therapeutic benefit in rheumatoid arthritis

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a debilitating autoimmune disease characterized by inflammation, pain, and joint destruction.
• Current RA treatments aim to reduce inflammation and halt disease progression but often have limitations like recurrence and adverse effects.
• These limitations necessitate novel therapeutic strategies for managing RA.

Purpose of the Study:

• To review the critical roles of specific transcription factors (TFs) in RA pathogenesis.
• To explore the potential of targeting these TFs for novel RA treatment strategies.
• To discuss the therapeutic implications of targeting NF-κB, STATs, AP-1, and IRFs in RA.

Main Methods:

• Literature review of scientific articles on RA, inflammation, and transcription factors.
• Analysis of the involvement of NF-κB, STATs, AP-1, and IRFs in RA-related inflammatory pathways.
• Evaluation of current and potential therapeutic interventions targeting these TFs.

Main Results:

• Identified four key transcription factors (NF-κB, STATs, AP-1, IRFs) central to RA inflammation.
• Demonstrated the role of these TFs in activating crucial inflammatory mediators in RA.
• Highlighted the potential of targeting these TFs with synthetic or natural compounds.

Conclusions:

• Transcription factors play a pivotal role in the inflammatory processes of rheumatoid arthritis.
• Targeting specific TFs like NF-κB, STATs, AP-1, and IRFs presents a promising avenue for developing more effective RA therapies.
• Further research into TF-targeted therapies could overcome limitations of current RA treatments.